How to cite item

Adjuvant EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: still an investigational approach

   
@article{TLCR31987,
	author = {Jacek Jassem},
	title = {Adjuvant EGFR tyrosine kinase inhibitors in  EGFR -mutant non-small cell lung cancer: still an investigational approach},
	journal = {Translational Lung Cancer Research},
	volume = {8},
	number = {Suppl 4},
	year = {2019},
	keywords = {},
	abstract = {The development of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have revolutionized treatment paradigms in lung cancer. Currently, EGFR TKIs constitute first- and second-line treatment of choice for EGFR-mutant advanced non-small cell lung cancer (NSCLC) patients. The first-generation TKIs (gefitinib, erlotinib and icotinib) have been supplemented by second (afatinib and dacomitinib) and third-generation (osimertinib) molecules. Several other EGFR-TKIs are currently being investigated in clinical trials (1).},
	issn = {2226-4477},	url = {https://tlcr.amegroups.org/article/view/31987}
}